These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16734973)

  • 1. Particulate delivery systems for vaccines: what can we expect?
    Bramwell VW; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity in response to particulate antigen-delivery systems.
    Storni T; Kündig TM; Senti G; Johansen P
    Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments.
    Heegaard PM; Dedieu L; Johnson N; Le Potier MF; Mockey M; Mutinelli F; Vahlenkamp T; Vascellari M; Sørensen NS
    Arch Virol; 2011 Feb; 156(2):183-202. PubMed ID: 21170730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Particulate vaccines: on the quest for optimal delivery and immune response.
    De Temmerman ML; Rejman J; Demeester J; Irvine DJ; Gander B; De Smedt SC
    Drug Discov Today; 2011 Jul; 16(13-14):569-82. PubMed ID: 21570475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery systems for molecular vaccination.
    Sheikh NA; al-Shamisi M; Morrow WJ
    Curr Opin Mol Ther; 2000 Feb; 2(1):37-54. PubMed ID: 11249651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
    Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
    J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers.
    Mishra N; Goyal AK; Tiwari S; Paliwal R; Paliwal SR; Vaidya B; Mangal S; Gupta M; Dube D; Mehta A; Vyas SP
    Expert Opin Ther Pat; 2010 May; 20(5):661-79. PubMed ID: 20345332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Particulate delivery systems for animal vaccines.
    Scheerlinck JP; Greenwood DL
    Methods; 2006 Sep; 40(1):118-24. PubMed ID: 16997719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products.
    Mohammed AR; Bramwell VW; Coombes AG; Perrie Y
    Methods; 2006 Sep; 40(1):30-8. PubMed ID: 16997711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
    Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal delivery of vaccines.
    Almeida AJ; Alpar HO
    J Drug Target; 1996; 3(6):455-67. PubMed ID: 8863138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the innate immune response with improved vaccine adjuvants.
    Pashine A; Valiante NM; Ulmer JB
    Nat Med; 2005 Apr; 11(4 Suppl):S63-8. PubMed ID: 15812492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary vaccine delivery.
    Lu D; Hickey AJ
    Expert Rev Vaccines; 2007 Apr; 6(2):213-26. PubMed ID: 17408371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvants--essential components of new generation vaccines].
    Dzierzbicka K; Kołodziejczyk AM
    Postepy Biochem; 2006; 52(2):204-11. PubMed ID: 17078510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticles and microparticles as vaccine-delivery systems.
    Singh M; Chakrapani A; O'Hagan D
    Expert Rev Vaccines; 2007 Oct; 6(5):797-808. PubMed ID: 17931159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?
    Bal SM; Ding Z; van Riet E; Jiskoot W; Bouwstra JA
    J Control Release; 2010 Dec; 148(3):266-82. PubMed ID: 20869998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
    Ahlers JD; Belyakov IM
    Eur J Immunol; 2009 Oct; 39(10):2657-69. PubMed ID: 19609978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.